Article
Histone deacetylase inhibition leads to regulatory histone mark alterations and impairs meiosis in oocytes
12 Aug 2021
Abstract excerpt
BACKGROUND: Panobinostat (PB), a histone deacetylase (HDAC) inhibitor drug, is clinically used in the treatment of cancers. We investigated the effects of PB on murine ovarian functions in embryos and adult animals. METHODS: C57BL/6J mice were treated with 5 mg/kg PB on alternate days from embryonic day (E) 6.5 to E15.5. We analysed the effects of PB on the ovaries by using immunofluorescence, gene expression...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
